Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932357 | 0.86 | APLNR (0.61) | HTR2AHTR2CPOLBATMCHRM2 | |
| SCHEMBL5267466 | 0.84 | ADRA1A (0.62) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| Hydrochloric Acid SCHEMBL28901936 | 0.84 | APLNR (0.59) | HTR2AHTR2CPOLBATMCHRM2 | |
| SCHEMBL1254174 | 0.81 | HTR2A (0.65) | ADRA1ATAAR1HTR2AHTR2CIDO1 | |
| SCHEMBL20153915 | 0.81 | ADRA1A (0.58) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| SCHEMBL8230324 | 0.81 | HTR2A (0.54) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| SCHEMBL8124998 | 0.81 | HTR2A (0.63) | TAAR1HTR2AHTR2CPOLBATM | |
| SCHEMBL5252421 | 0.81 | IDO1 (0.66) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| SCHEMBL6506680 | 0.80 | ADRA1A (0.57) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| SCHEMBL5154843 | 0.79 | ADRA1A (0.70) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2835648-B1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | RANDOX LABORATORIES LTD (GB) | 2018-12-12 | — | — | EP | claimed |
| EP-2835648-A1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | Randox Laboratories Ltd. (GB) | 2015-02-11 | — | — | EP | claimed |
| US-20150038366-A1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | NORTHERN BANK LIMITED (IE) | 2015-02-05 | — | — | US | claimed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-10775394-B2 | Immunoassay for phenethylamines of the 2C and DO sub-families | RANDOX LABORATORIES LIMITED (GB) | 2020-09-15 | — | — | US | disclosed |
| EP-2835648-B1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | RANDOX LABORATORIES LTD (GB) | 2018-12-12 | — | — | EP | disclosed |
| US-20180209998-A1 | IMMUNOASSAY FOR PHENETHYLAMINES OF THE 2C AND DO SUB-FAMILIES | RANDOX LABORATORIES LIMITED | 2018-07-26 | — | — | US | disclosed |
| US-9945877-B2 | Immunoassay for phenethylamines of the 2C and DO sub-families | RANDOX LABORATORIES LIMITED (GB) | 2018-04-17 | — | — | US | disclosed |
| EP-2835648-A1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | Randox Laboratories Ltd. (GB) | 2015-02-11 | — | — | EP | disclosed |
| US-20150038366-A1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | NORTHERN BANK LIMITED (IE) | 2015-02-05 | — | — | US | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2009099582-A2 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| WO-2008011518-A2 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007146786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING B-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006074051-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10775394-B2 | Immunoassay for phenethylamines of the 2C and DO sub-families | PNMT, DDT, COMT | ADRA1A 565/4885TAAR1 514/4885MTNR1A 839/4885 |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | ADRA1A 3488/4885TAAR1 4461/4885MTNR1A 230/4885 |
| US-20180209998-A1 | IMMUNOASSAY FOR PHENETHYLAMINES OF THE 2C AND DO SUB-FAMILIES | PNMT, DDT, COMT | ADRA1A 565/4885TAAR1 514/4885MTNR1A 839/4885 |
| US-20150038366-A1 | Immunoassay for Phenethylamines of the 2C and DO Sub-Families | PNMT, DDT, COMT | ADRA1A 565/4885TAAR1 514/4885MTNR1A 839/4885 |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | IAPP, PNLIP, AMY2A | ADRA1A 268/4885TAAR1 4140/4885MTNR1A 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.